Study to Investigate the Effect of the A1 Agonist Capadenoson on Ventricular HR in Patients With Persistent or Permanent Atrial Fibrillation.

Study to Investigate the Effect of the A1 Agonist Capadenoson on Ventricular HR in Patients With Persistent or Permanent Atrial Fibrillation by Administration of Capadenoson in a Dose of 4 mg Once Daily for Five Days

This trial has the primary goal to show that BAY68-4986 can lower the ventricular rate in patients with the indication persistent atrial fibrillation.

Inclusion Criteria:

• Male and/or female (without childbearing potential) white patients
• History of persistent or permanent atrial fibrillation
• 18 to 75 years of age

Exclusion Criteria:

• Patients with high-risk cardiovascular diseases
• Stroke or myocardial infarction
• Relevant pathological changes in the ECG or echocardiography
• Medication affecting ventricular response in Afib